You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium Sulfate
Accession NumberDB00653  (APRD01080)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
Structure
Thumb
Synonyms
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulphate
Magnesium(ii) sulfate
Magnesiumsulfat
MgSO4
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousGENERAL INJECTABLES AND VACCINES, INC.2015-09-16Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2000-08-08Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousCardinal Health2000-08-08Not applicableUs
Magnesium SulfateInjection, solution4 g/100mLIntravenousHospira, Inc.1994-06-24Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2016-01-29Not applicableUs
Magnesium SulfateInjection, solution4 g/50mLIntravenousHospira, Inc.1994-06-24Not applicableUs
Magnesium Sulfate DressingLiquid45 %TopicalDumex Medical Canada Inc.Not applicableNot applicableCanada
Magnesium Sulfate In DextroseInjection, solution10 mg/mLIntravenousHospira, Inc.1995-07-11Not applicableUs
Magnesium Sulfate In DextroseInjection, solution20 mg/mLIntravenousHospira, Inc.1995-07-11Not applicableUs
Magnesium Sulfate Inj 20% USPLiquid200 mgIntramuscular; IntravenousSandoz Canada Incorporated1978-12-31Not applicableCanada
Magnesium Sulfate Inj 50%Liquid500 mgIntramuscularKripps Pharmacy Ltd.1980-12-31Not applicableCanada
Magnesium Sulfate Inj 50%Liquid500 mgIntramuscular; IntravenousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Magnesium Sulfate Inj 500mg/mlSolution500 mgIntramuscular; IntravenousAbbott Laboratories, Limited1981-12-311999-04-01Canada
Magnesium Sulfate InjectionSolution500 mgIntramuscular; IntravenousFresenius Kabi Canada Ltd1992-12-31Not applicableCanada
Magnesium Sulfate Injection 50% USPLiquid500 mgIntramuscular; IntravenousSandoz Canada Incorporated1984-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium SulfateInjection, solution80 mg/mLIntravenousFresenius Kabi USA, LLC2016-03-15Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousX Gen Pharmaceuticals, Inc.2014-02-23Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousHospira, Inc.2000-04-25Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousHospira, Inc.1987-07-22Not applicableUs
Magnesium SulfateInjection, solution5 g/10mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2006-12-12Not applicableUs
Magnesium SulfateInjection, solution40 mg/mLIntravenousFresenius Kabi USA, LLC2016-03-15Not applicableUs
Magnesium SulfateInjection1 g/100mLIntravenousWG Critical Care, LLC2016-03-08Not applicableUs
Magnesium Sulfate In 5% DextroseInjection, solution1 g/100mLIntravenousFresenius Kabi USA, LLC2016-03-07Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Assured Epsom SaltGranule100 g/100gOralGreenbrier International, Inc.2016-06-14Not applicableUs
Assured Epsom SaltGranule100 g/100gOralHefei Yatai Daily Chemical Products Co., Ltd.2016-03-30Not applicableUs
Epsom SaltGranule1 g/gOralPublix Super Markets, Inc.,2013-07-03Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWalgreens2015-07-13Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalSUPERVALU INC.2005-03-21Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalLiberty Procurement, Inc2016-07-11Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalKroger Co.1993-10-21Not applicableUs
Epsom SaltGranule1 g/gOral; TopicalTOP CARE (Topco Associates LLC)2014-04-30Not applicableUs
Epsom SaltGranule, for solution100 g/100gOral; TopicalGood Neighbor Pharmacy2010-01-01Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalDZA Brands, LLC2008-02-27Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalMeijer Distribution, Inc2015-07-21Not applicableUs
Epsom SaltGranule1 g/gOral; TopicalWalgreens2016-04-30Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWakefern Food Corp2014-05-01Not applicableUs
Epsom SaltGranule, for solution1 g/gOralCVS Pharmacy1998-07-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalTOPCO ASSOCIATES, LLC1999-07-15Not applicableUs
Epsom SaltGranule100 g/100gOralFrog Prince(china)daily Chemicals Co., Ltd.2016-09-05Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalSAFEWAY INC2002-11-12Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalDolgencorp, LLC1993-10-21Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalGeiss, Destin and Dunn, Inc1992-07-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalFoodhold U.S.A., Llc2015-05-06Not applicableUs
Epsom SaltGranule1.81 kg/100kgOral; TopicalKinray, Inc.2012-06-14Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalTarget Corporation1996-12-12Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalMeijer Distribution, Inc2013-04-26Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalDiscount Drug Mart2002-12-02Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalShop Ko Stores Operating Co., Llc2009-06-05Not applicableUs
Epsom SaltGranule1 g/gOral; TopicalMc Kesson (Sunmark)2014-08-18Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalFoodhold U.S.A., Llc2015-05-06Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalWinCo Foods, LLC2015-05-21Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalPublix Super Markets, Inc2014-09-05Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalVi Jon1998-07-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalValu Merchandisers, Co.2014-10-15Not applicableUs
Epsom SaltGranule, for solution1 g/gOral; TopicalYour Military Exchange2002-12-18Not applicableUs
Epsom SaltGranule100 kg/100kgOralWestern Family1998-06-05Not applicableUs
Epsom SaltCrystal1 g/gOral; TopicalCardinal Health2012-03-26Not applicableUs
Epsom Salt Magnesium SulfateGranule1 g/gOral; TopicalCVS Pharmacy2014-12-31Not applicableUs
Epsom Salt Pws 100%Powder, for solution100 %OralJedmon Products Ltd.1990-12-312006-03-22Canada
Epsom Salt Soaking SolutionGranule2.72 kg/2.72kgTopicalAdvanced Beauty Systems, Inc.2012-06-13Not applicableUs
Epsom SaltsPowderOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1972-12-312000-07-27Canada
Epsom SaltsPowder100 %OralLawton's Drug Stores Ltd.1987-12-311997-04-02Canada
Epsom SaltsPowderOralDawson Traders Ltd.1977-12-312006-03-22Canada
Epsom SaltsPowder100 %OralR.W. Packaging Ltd.1987-12-312004-07-21Canada
Epsom Salts ReliefGranule100 g/100gOralBlue Cross Laboratories, Inc.2010-07-09Not applicableUs
Eucalyptus Scented Natural Epsom SaltPowder10 g/10gTopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2016-01-26Not applicableUs
Eucalyptus Scented Natural Epsom SaltPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-26Not applicableUs
Green Tea Chamomile Natural Epsom SaltPowder10 g/10gTopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2016-01-26Not applicableUs
Green Tea Chamomile Natural Epsom SaltPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-26Not applicableUs
Health Smart Natural Epsom SaltGranule, for solution1 g/gOralInternational Wholesale, Inc.2013-08-01Not applicableUs
Health Smart Natural Epsom SaltGranule, for solution1 g/gOralInternational Wholesale, Inc.2013-08-01Not applicableUs
Humco Epson SaltPowder, for solution1000 mg/gOralHumco Holding Group, Inc.1998-03-25Not applicableUs
Lucky Epsom SaltGranule100 g/100gOralDelta Brands Inc2016-09-05Not applicableUs
Morton Natural Epsom SaltGranule, for solution1 kg/kgOral; TopicalMorton Salt, Inc.2012-09-01Not applicableUs
Natural Epsom SaltPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-26Not applicableUs
Natural Epsom SaltPowder10 g/10gTopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2014-10-09Not applicableUs
Natural Epsom SaltPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-27Not applicableUs
Natural Epsom SaltPowder10 g/10gTopicalMy Import USA Inc2014-10-09Not applicableUs
Natural Epsom Salt LavenderPowder10 g/10gTopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2016-01-26Not applicableUs
Natural Epsom Salt LavenderPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-26Not applicableUs
Natural Epsom SaltsCrystal100 g/100gOral; TopicalFirst Aid Research Corp.2015-05-15Not applicableUs
Royal Epsom SaltGranule, for solution1 kg/kgOralFilo America2014-10-29Not applicableUs
Sel D EpsomPowderOralProduits Marc O (1987) Inc., Division Of Technilab Inc.1989-12-152000-08-24Canada
Spearmint and Menthol Scented Natural Epsom SaltPowder10 g/10gTopicalPoint Guard Marketing Inc.2016-01-27Not applicableUs
Spearmint and Menthol Scented Natural Epsom SaltPowder10 g/10gTopicalAnhui Twowin Machinery Imp. & Exp. Co., Ltd.2016-01-27Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousCardinal Health2000-08-08Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Magnesium SulfateInjection, solution20 g/250mLIntravenousCantrell Drug Company2011-07-25Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Magnesium SulfateInjection500 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Magnesium SulfateInjection, solution500 mg/mLIntramuscular; IntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
Magnesium SulfateInjection, solution.5 g/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Magnesium SulfateInjection, solution20 g/500mLIntravenousCantrell Drug Company2011-02-21Not applicableUs
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Concept DHAUs Pharmaceutical Corporation
Concept ObUs Pharmaceutical Corporation
Eau Purgative RigaGlendale Agencies
Magnesium CapAlsi Cie Ltee
Magnesium Sulfate In 5% Dextrose Inj(20mg/ml)Hospira Healthcare Corporation
Multiple Electrolyte Additive InjInternational Medication Systems Ltd.
Solution CardaLaboratoire Atlas Inc
Suprep Bowel PrepBraintree Laboratories, Inc.
Tandem ObUs Pharmaceutical Corporation
Tandem PlusUs Pharmaceutical Corporation
Vamin NFresenius Kabi Ab
Salts
Name/CASStructureProperties
Magnesium sulfate heptahydrate
ThumbNot applicableDBSALT001240
Categories
UNIIML30MJ2U7I
CAS number7487-88-9
WeightAverage: 120.368
Monoisotopic: 119.936771076
Chemical FormulaMgO4S
InChI KeyCSNNHWWHGAXBCP-UHFFFAOYSA-L
InChI
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
IUPAC Name
magnesium(2+) ion sulfate
SMILES
[Mg++].[O-]S([O-])(=O)=O
Pharmacology
IndicationUsed for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.
Structured Indications
PharmacodynamicsMagnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.
Mechanism of actionMagnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent calcium channel gamma-1 subunitProteinunknownNot AvailableHumanQ06432 details
Voltage-dependent calcium channel subunit alpha-2/delta-1ProteinunknownNot AvailableHumanP54289 details
Voltage-dependent L-type calcium channel subunit alpha-1CProteinunknownNot AvailableHumanQ13936 details
Voltage-dependent L-type calcium channel subunit beta-1ProteinunknownNot AvailableHumanQ02641 details
Voltage-dependent L-type calcium channel subunit beta-2ProteinunknownNot AvailableHumanQ08289 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinunknownNot AvailableHumanQ13698 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding25-30%
Metabolism

None

Route of eliminationMagnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.
Half life43.2 hours (for newborns)
ClearanceNot Available
ToxicityLD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Magnesium Sulfate.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Magnesium Sulfate.Vet Approved
7-NitroindazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcepromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
adipiplonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
AlfacalcidolThe serum concentration of Magnesium Sulfate can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlfaxaloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
AlphacetylmethadolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmisulprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium Sulfate.Approved
AmobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Magnesium Sulfate.Approved
AmoxapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Magnesium Sulfate.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium Sulfate.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Magnesium Sulfate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Magnesium Sulfate.Approved, Investigational
AripiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Magnesium Sulfate.Approved
ArticaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Atosiban.Approved
Atracurium besylateMagnesium Sulfate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium Sulfate.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium Sulfate.Investigational
BaclofenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Magnesium Sulfate.Experimental
BarbexacloneThe metabolism of Magnesium Sulfate can be increased when combined with Barbexaclone.Experimental
BarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium Sulfate.Approved
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium Sulfate.Approved
BenperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Magnesium Sulfate.Approved
Benzyl alcoholMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium Sulfate.Approved, Withdrawn
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Magnesium Sulfate.Approved
BrexpiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BrompheniramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Magnesium Sulfate.Investigational
BupivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Magnesium Sulfate.Approved
ButethalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Magnesium Sulfate.Approved
ButorphanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CaiThe risk or severity of adverse effects can be increased when Cai is combined with Magnesium Sulfate.Investigational
CalcitriolThe serum concentration of Magnesium Sulfate can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CalciumThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Magnesium Sulfate.Withdrawn
CarbamazepineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarbomycinThe metabolism of Magnesium Sulfate can be decreased when combined with Carbomycin.Vet Approved
CarfentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarisoprodolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Magnesium Sulfate.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Magnesium Sulfate.Approved
CetirizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Magnesium Sulfate.Approved
ChlorphenamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlortetracyclineMagnesium Sulfate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorzoxazoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Magnesium Sulfate.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium Sulfate.Approved
CimetidineThe serum concentration of Magnesium Sulfate can be increased when it is combined with Cimetidine.Approved
CinchocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium Sulfate.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
Cisatracurium besylateMagnesium Sulfate may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CitalopramThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Citalopram.Approved
ClarithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Clarithromycin.Approved
ClemastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Sulfate.Approved
ClidiniumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
clomethiazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Magnesium Sulfate.Approved, Nutraceutical
ClorazepateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Magnesium Sulfate.Approved, Vet Approved
ClozapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Magnesium Sulfate.Investigational
CyclizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
CyproheptadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Magnesium Sulfate.Investigational
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium Sulfate.Experimental
DecamethoniumMagnesium Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Magnesium Sulfate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium Sulfate.Approved
DemeclocyclineMagnesium Sulfate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
deramciclaneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DesfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Desvenlafaxine.Approved
DetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DifenoxinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium Sulfate.Approved
DimenhydrinateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium Sulfate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium Sulfate.Approved
Domoic AcidMagnesium Sulfate may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DoramectinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium Sulfate.Investigational
Doxacurium chlorideMagnesium Sulfate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
DoxepinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxycyclineMagnesium Sulfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DoxylamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
DrotebanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Duloxetine.Approved
DyclonineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Magnesium Sulfate.Approved
EcopipamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Magnesium Sulfate.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium Sulfate.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium Sulfate.Approved
EnfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium Sulfate.Approved
EntacaponeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium Sulfate.Approved, Investigational
ErythromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Escitalopram.Approved, Investigational
EstazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
EtifoxineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtizolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Etoperidone.Approved
EtorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Sulfate.Approved, Investigational
FencamfamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium Sulfate.Withdrawn
FentanylMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium Sulfate.Approved
FlibanserinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluconazoleThe serum concentration of Magnesium Sulfate can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Magnesium Sulfate.Approved
FludiazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Magnesium Sulfate.Withdrawn
FlunarizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Magnesium Sulfate.Approved
FospropofolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
GabapentinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gallamine TriethiodideMagnesium Sulfate may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium Sulfate.Investigational
Gamma Hydroxybutyric AcidMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
GepironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Magnesium Sulfate.Experimental
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium Sulfate.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Magnesium Sulfate.Approved, Vet Approved
GuanfacineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Magnesium Sulfate.Approved, Withdrawn
HalothaneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Magnesium Sulfate.Approved
HexobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HydrocodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
IloperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Indalpine.Investigational, Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Magnesium Sulfate.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Magnesium Sulfate.Approved
IsofluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium Sulfate.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Magnesium Sulfate.Approved, Investigational
JosamycinThe metabolism of Magnesium Sulfate can be decreased when combined with Josamycin.Approved
KetamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Magnesium Sulfate.Approved, Investigational
KitasamycinThe metabolism of Magnesium Sulfate can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Magnesium Sulfate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium Sulfate.Approved
LamotrigineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium Sulfate.Approved, Investigational
LevetiracetamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
Levomethadyl AcetateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Levomilnacipran.Approved
LevorphanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium Sulfate.Approved
LidocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
Lipoic AcidMagnesium Sulfate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LithiumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
LoratadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LoxapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LurasidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium Sulfate.Approved
MaprotilineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MeclizineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mefloquine.Approved
MelatoninMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MepivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MesoridazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaxaloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylphenobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetocurineMagnesium Sulfate may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium Sulfate may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetyrosineMagnesium Sulfate may increase the sedative activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Magnesium Sulfate.Experimental
MianserinThe therapeutic efficacy of Magnesium Sulfate can be decreased when used in combination with Mianserin.Approved
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium Sulfate.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Magnesium Sulfate.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
MidazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Milnacipran.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Magnesium Sulfate.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Investigational
MirtazapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumMagnesium Sulfate may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Magnesium Sulfate.Vet Approved
MorphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Sulfate.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Magnesium Sulfate.Experimental
NabiloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NafcillinThe metabolism of Magnesium Sulfate can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium Sulfate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium Sulfate.Investigational
NalbuphineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Magnesium Sulfate.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Magnesium Sulfate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Nefazodone.Approved, Withdrawn
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
NeosaxitoxinMagnesium Sulfate may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium Sulfate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium Sulfate.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Sulfate.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium Sulfate.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium Sulfate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium Sulfate.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium Sulfate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium Sulfate.Approved
NitrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate.Approved
NitroprussideMagnesium Sulfate may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Magnesium Sulfate.Approved
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
NormethadoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Magnesium Sulfate.Approved, Vet Approved
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
OlanzapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OleandomycinThe metabolism of Magnesium Sulfate can be decreased when combined with Oleandomycin.Vet Approved
OlopatadineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrlistatThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxetacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Magnesium Sulfate.Approved
OxprenololMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
OxytetracyclineMagnesium Sulfate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Magnesium Sulfate.Investigational
PaliperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Sulfate.Approved
PancuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine.Approved, Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Magnesium Sulfate.Approved
PentazocineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
PerazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium Sulfate.Approved
PerospironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoxyethanolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Magnesium Sulfate.Approved, Vet Approved
PimozideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium Sulfate.Approved
PipamperoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipecuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PiritramideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PizotifenMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Polystyrene sulfonate.Approved
PomalidomideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
PramipexoleMagnesium Sulfate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
PregabalinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanoloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium Sulfate.Withdrawn
PrilocaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProchlorperazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
ProparacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium Sulfate.Investigational
PSD502Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PyrantelMagnesium Sulfate may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
RacloprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Magnesium Sulfate.Experimental
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium Sulfate.Approved
RamelteonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RapacuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
RifabutinThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Rifapentine.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Sulfate.Approved, Investigational
RisperidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RocuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Rocuronium.Approved
RomifidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleMagnesium Sulfate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium Sulfate.Approved
RotigotineMagnesium Sulfate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Magnesium Sulfate.Approved
S-EthylisothioureaMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
Sage 547Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Magnesium Sulfate.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium Sulfate.Approved, Vet Approved
ScopolamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Magnesium Sulfate.Approved
SertindoleMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Sertraline.Approved
SevofluraneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Magnesium Sulfate.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Magnesium Sulfate.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Magnesium Sulfate.Approved, Investigational
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium Sulfate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
Sodium phosphateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium Sulfate.Approved
SolithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Solithromycin.Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium Sulfate.Approved
StiripentolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SuccinylcholineMagnesium Sulfate may increase the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Magnesium Sulfate.Approved
SulpirideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SuvorexantMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Investigational
TandospironeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved
TasimelteonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Magnesium Sulfate.Approved
Technetium tc 99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Magnesium Sulfate.Approved
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium Sulfate.Approved
TelithromycinThe metabolism of Magnesium Sulfate can be decreased when combined with Telithromycin.Approved
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Magnesium Sulfate.Withdrawn
TemazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TerazosinTerazosin may increase the hypotensive activities of Magnesium Sulfate.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Magnesium Sulfate.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Magnesium Sulfate.Approved
TetrabenazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetracyclineMagnesium Sulfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TetrodotoxinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixeneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Magnesium Sulfate.Approved
TiagabineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TiletamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Magnesium Sulfate.Approved
TizanidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Magnesium Sulfate.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Magnesium Sulfate.Approved, Vet Approved
TopiramateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium Sulfate.Approved, Investigational
Trans-2-PhenylcyclopropylamineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TriazolamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TriethylenetetramineThe serum concentration of Magnesium Sulfate can be decreased when it is combined with Triethylenetetramine.Approved
TrifluoperazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Magnesium Sulfate.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Magnesium Sulfate.Approved, Investigational
TrimipramineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TroleandomycinThe metabolism of Magnesium Sulfate can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Withdrawn
TubocurarineMagnesium Sulfate may increase the neuromuscular blocking activities of Tubocurarine.Approved
TylosinThe metabolism of Magnesium Sulfate can be decreased when combined with Tylosin.Vet Approved
Uc1010Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
Valproic AcidMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VecuroniumMagnesium Sulfate may increase the neuromuscular blocking activities of Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium Sulfate.Approved
VigabatrinMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium Sulfate.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Magnesium Sulfate.Approved, Investigational
VortioxetineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XylazineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Sulfate.Approved
ZaleplonMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Zimelidine.Withdrawn
ZiprasidoneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Sulfate.Approved
ZolpidemMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Shinichi Yamamoto, Akifumi Sekitani, “BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF.” U.S. Patent US20110042297, issued February 24, 2011.

US20110042297
General References
  1. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. [PubMed:16002955 ]
  2. Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, Kono Y, Honma Y, Momoi MY: Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010 Mar;86(3):187-91. doi: 10.1016/j.earlhumdev.2010.02.007. Epub 2010 Mar 12. [PubMed:20226604 ]
  3. Wedig KE, Kogan J, Schorry EK, Whitsett JA: Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006 Jun;26(6):371-4. [PubMed:16724078 ]
  4. Nassar AH, Sakhel K, Maarouf H, Naassan GR, Usta IM: Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scand. 2006;85(9):1099-103. [PubMed:16929415 ]
  5. Malaeb SN, Rassi AI, Haddad MC, Seoud MA, Yunis KA: Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labour. Pediatr Radiol. 2004 May;34(5):384-6. Epub 2004 Feb 18. [PubMed:14985884 ]
  6. Matsuda Y, Maeda Y, Ito M, Sakamoto H, Masaoka N, Takada M, Sato K: Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8. [PubMed:9286718 ]
  7. Schanler RJ, Smith LG Jr, Burns PA: Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41. [PubMed:9194621 ]
  8. Santi MD, Henry GW, Douglas GL: Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994 Mar-Apr;14(2):249-53. [PubMed:8188843 ]
  9. Holcomb WL Jr, Shackelford GD, Petrie RH: Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991 Oct;78(4):611-4. [PubMed:1923163 ]
  10. Cumming WA, Thomas VJ: Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR Am J Roentgenol. 1989 May;152(5):1071-2. [PubMed:2705341 ]
  11. Lamm CI, Norton KI, Murphy RJ, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr. 1988 Dec;113(6):1078-82. [PubMed:3193315 ]
  12. McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM: Effects of magnesium sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980 Nov;56(5):595-600. [PubMed:7432730 ]
  13. Riaz M, Porat R, Brodsky NL, Hurt H: The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998 Nov-Dec;18(6 Pt 1):449-54. [PubMed:9848759 ]
External Links
ATC CodesA06AD04V04CC02A12CC02B05XA05D11AX05
AHFS Codes
  • 28:12.92
  • 40:12.00
  • 56:12.00
  • 84:92.00
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7487
Blood Brain Barrier+0.9646
Caco-2 permeable-0.6267
P-glycoprotein substrateNon-substrate0.9137
P-glycoprotein inhibitor INon-inhibitor0.9194
P-glycoprotein inhibitor IINon-inhibitor0.9904
Renal organic cation transporterNon-inhibitor0.9521
CYP450 2C9 substrateNon-substrate0.8775
CYP450 2D6 substrateNon-substrate0.8213
CYP450 3A4 substrateNon-substrate0.7007
CYP450 1A2 substrateNon-inhibitor0.7767
CYP450 2C9 inhibitorNon-inhibitor0.7602
CYP450 2D6 inhibitorNon-inhibitor0.9115
CYP450 2C19 inhibitorNon-inhibitor0.7547
CYP450 3A4 inhibitorNon-inhibitor0.9759
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9577
Ames testNon AMES toxic0.5773
CarcinogenicityCarcinogens 0.8111
BiodegradationReady biodegradable0.943
Rat acute toxicity2.4160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7988
hERG inhibition (predictor II)Non-inhibitor0.9446
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abraxis pharmaceutical products
  • Hospira inc
Packagers
Dosage forms
FormRouteStrength
Capsule, liquid filledOral
CapsuleOral
LiquidOral
CrystalOral; Topical1 g/g
GranuleOral1 g/g
GranuleOral100 kg/100kg
GranuleOral; Topical1.81 kg/100kg
Granule, for solutionOral; Topical1 g/g
Granule, for solutionOral; Topical100 g/100g
GranuleOral; Topical1 g/g
Powder, for solutionOral100 %
GranuleTopical2.72 kg/2.72kg
PowderOral
PowderOral100 %
GranuleOral100 g/100g
Granule, for solutionOral1 g/g
Powder, for solutionOral1000 mg/g
InjectionIntramuscular; Intravenous500 mg/mL
InjectionIntravenous1 g/100mL
Injection, solutionIntramuscular; Intravenous.5 g/mL
Injection, solutionIntramuscular; Intravenous5 g/10mL
Injection, solutionIntramuscular; Intravenous500 mg/mL
Injection, solutionIntravenous20 g/500mL
Injection, solutionIntravenous20 g/250mL
Injection, solutionIntravenous4 g/50mL
Injection, solutionIntravenous4 g/100mL
Injection, solutionIntravenous40 mg/mL
Injection, solutionIntravenous80 mg/mL
LiquidTopical45 %
Injection, solutionIntravenous1 g/100mL
SolutionIntravenous
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
LiquidIntramuscular; Intravenous200 mg
LiquidIntramuscular500 mg
SolutionIntramuscular; Intravenous500 mg
LiquidIntramuscular; Intravenous500 mg
Granule, for solutionOral; Topical1 kg/kg
LiquidIntravenous
PowderTopical10 g/10g
CrystalOral; Topical100 g/100g
Granule, for solutionOral1 kg/kg
Solution, concentrateOral
Prices
Unit descriptionCostUnit
Elliotts b solution ampule4.71USD ml
Magnesium Sulfate 50% Solution 2ml Vial0.92USD vial
Magnesium sulfate powder0.29USD g
Magnesium-ns 6 g/50 ml bag0.29USD ml
Magnesium-ns 4 g/50 ml bag0.27USD ml
Magnesium-ns 3 g/50 ml bag0.26USD ml
Magnesium sulfate-ns 2 gm bag0.25USD ml
Magnesium sulfate-ns 1 gm bag0.24USD ml
Magnesium-d5w 1 gm/100 ml soln0.07USD ml
Magnesium-lr 20 g/500 ml0.03USD ml
Magnesium-lr 40 g/500 ml bag0.03USD ml
Magnesium-lr 50 g/500 ml bag0.02USD ml
Epsom salt 100% powder0.01USD g
Magnesium sulf 4% iv soln0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6946149 No2003-03-072023-03-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point1124 °C (decomposition)Not Available
water solubility710 mg/mLNot Available
logP-0.91Not Available
Predicted Properties
PropertyValueSource
logP-0.84ChemAxon
pKa (Strongest Acidic)-3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.26 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity11.53 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as alkaline earth metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassAlkaline earth metal oxoanionic compounds
Sub ClassAlkaline earth metal sulfates
Direct ParentAlkaline earth metal sulfates
Alternative Parents
Substituents
  • Alkaline earth metal sulfate
  • Inorganic oxide
  • Inorganic salt
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:39